Profesores e Investigadores

Departamentos

Curriculum Vitae

Raquel Abalo Delgado
Catedrático/a de Universidad
Coordinador/a General del Programa de Doctorado de CC. de la Salud
4
Quinquenios
2020
6
Docentia
2022-23
4
Sexenios investigación
2022

Centro

Fac. de CC. de la Salud

Departamento

Ciencias Básicas de la Salud

Área

Farmacología

Grupo de investigación

Grupo de investigación de alto rendimiento en Fisiopatología y Farmacología del sistema digestivo de la Universidad Rey Juan Carlos / Research group in Physiopathology and Pharmacology of the digestive system at Universidad Rey Juan Carlos

Grupo docente

Grupo de Innovación Docente Emergente en Enseñanza-Aprendizaje en Salud

Contacto

raquel.abalo@urjc.es
Información general
Información general
Presentación

  • Full professor of Pharmacology (December 2017-), Functional Coordinator of the Area of Pharmacology and Nutrition (January 2018-), and Coordinator of the PhD Program on Health Sciences (October 2021-). 5 Docentia (last one: 2019-20), 4 5-year teaching (last one: 2016-20) and 4 6-year research (last one: 2017-22) periods.  Principal investigator of the Research Group NeuGut (URJC), interested in the physiopathology and pharmacology of the gastrointestinal (GI) tract. Our group was the first to characterize the enteric neuropathies occurring as sequelae of chemotherapy in preclinical models, and to determine the effects of cannabinoid agonists and antagonists to alleviate/prevent the associated GI motility alterations. GI motility alterations associated with aging, obesity, metabolic syndrome and diabetes and pharmacologic and nutritional therapeutic strategies are also being addressed in our lab. We have developed our own methods to evaluate GI tract motility in experimental animals, which have been adopted by other groups. We are interested in characterizing, using sophisticated computerized methods in collaboration with engineers (fluoroscopy, ultrasound vocalization), subtle alterations of GI motility and visceral sensitivity present in models of irritable bowel syndrome, metabolic syndrome and schizophrenia, and differences associated to gender. Close collaborators: Dr. Uranga (URJC), Dr. Fichna (U. Lodz, Poland), Dr. Nurgali (Victoria U., Australia), Dr. Soto-Montenegro (IiSGM, Madrid) and Dr. del Castillo (CIAL-CSIC-UAM, Madrid).  

    32 research projects (7 as Principal Investigator). 16 research contracts. 83 articles in indexed journals (>80% as first/last/corresponding author), 10 articles in non-indexed journals, 14 chapters in national books, 14 chapters in international books, 3 e-books as guest editor (Frontiers in Pharmacology; Nutrients). 14 invited talks at national (9) and international (5) meetings and 10 talks at different national (4) and international institutions (6). Supervisor of 4 PhD theses (2 with European Mention and Doctorate Extraordinary Award), 13 Final Master Assays and 64 Final Degree Assays, as well as several students from other national and international institutions during their degree practical/predoctoral training in our lab. Reviewer of more than 180 manuscripts in more than 50 indexed journals, 1 international book chapter and more than 40 research projects for international entities. Member of the editorial board of the journals Neurogastroenterology and Motility (from May 2018) and Frontiers in Pharmacology (from April 2021). Co-director of the Annual Madrid Meeting of Pharmacologists in 2017 (Farmadrid 26).

Méritos
Docencia y asignaturas impartidas en el curso actual

  • Grado

    PLAN ASIGNATURA
    (2035) GRADO EN ENFERMERIA (ALCORCON)FARMACOLOGIA. NUTRICION Y DIETETICA
    (2340) GRADO EN FARMACIA (ALCORCON)FARMACOLOGIA I
    (2340) GRADO EN FARMACIA (ALCORCON)FARMACOLOGIA II
    (2229) GRADO EN INGENIERIA BIOMEDICA (FUENLABRADA)FARMACOLOGIA
    (2291) GRADO EN INGENIERIA BIOMEDICA (INGLES) (ALCORCON)PHARMACOLOGY
    (2000) GRADO EN MEDICINA (ALCORCON)FARMACOLOGIA
HISTÓRICO DOCENTE (ÚLTIMOS 10 CURSOS ACADÉMICOS)

Listado de proyectos (Últimos 10 años)
Códigos de investigador
Publicaciones

  • 1. Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, Rudd JA, Abalo R (2022). Mechanisms of chemotherapy-induced neurotoxicity. Front. Pharmacol.. doi: 10.3389/fphar.2022.750507. (Q1) (in press). 

    2. Fernández J, Silván B, Entrialgo R, Villar CJ, Capasso R, Uranga JA, Lombó F, Abalo R (2021).     Antiproliferative and palliative activity of flavonoids in colorectal cancer. Biomed Pharmacother. Nov;143:112241. doi: 10.1016/j.biopha.2021.112241. (Q1, D1).     

    3. Abalo R (2021). Coffee and Caffeine Consumption for Human Health (Editorial). Nutrients, 13, 2918.     https://doi.org/10.3390/nu13092918. (Q1). 

    4. Bagüés A, López-Tofiño Y, Gálvez-Robleño C, Abalo R (2021).     Effects of two different acute and subchronic stressors on gastrointestinal transit in the rat: a radiographic analysis. Neurogastroenterol Motil. 2021 Nov;33(11):e14232.. doi: 10.1111/nmo.14232. (Q2).     

    5. Jacenik D, Bagüés A, López-Gómez L, López-Tofiño Y, Iriondo-DeHond A, Serra C, Banovcanová L, Gálvez-Robleño C, Fichna J, Del Castillo MD, Uranga JA, Abalo R (2021).     Changes in Fatty Acid Dietary Profile Affect the Brain-Gut Axis Functions of Healthy Young Adult Rats in a Sex-Dependent Manner. Nutrients. May 30;13(6):1864. doi: 10.3390/nu13061864. (Q1).     

    6. Iriondo-DeHond A, Uranga JA, del Castillo MD, Abalo R (2020.     Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain¿Gut Axis. Nutrients, 13 (1), E88. https://doi.org/10.3390/nu13010088. (Q1).     

    7. Martínez V, Iriondo De-Hond A, Borrelli F, Capasso R, del Castillo MD, Abalo R (2020).     Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders. Useful nutraceuticals? Int. J. Mol. Sci., 21, 3067; doi:10.3390/ijms21093067. (Q1).     

    8. Uranga JA, Vera G, Abalo R (2018). Cannabinoid pharmacology and therapy in gut disorders. Biochem. Pharmacol. 2018 Nov;157:134-147. doi: 10.1016/j.bcp.2018.07.048. (Q1, D1).     

    9. Nurgali K, Jagoe RT, Abalo R, eds. (2018). Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae? Lausanne: Frontiers Media. doi: 10.3389/978-2-88945-482-2. ISBN: 978-2-88945-482-2. (Frontiers Research Topic - Frontiers in Pharmacology: Q1).     

    10. McQuade R, Petersen AC, Abalo R, Bornstein JC, Rybalka E, Nurgali K (2018). Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15.     Br J Pharmacol. 175(4):656-677. doi: 10.1111/bph.14114. (Q1, D1).

2024 © Universidad Rey Juan Carlos